Sciwind Biosciences Overview
- Year Founded
-
2017
- Status
-
IPO Registration
- Employees
-
8
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
11
Sciwind Biosciences General Information
Description
Developer of novel medicines designed for weight management. The company provides research and commercialization, enabling healthcare industry users with global patient-focused solutions.
Contact Information
Website
www.sciwindbio.comCorporate Office
- 9th Floor, Building 2
- Number 400 Fucheng Road, Qiantang District
- Hangzhou, Zhejiang 310018
- China
Corporate Office
- 9th Floor, Building 2
- Number 400 Fucheng Road, Qiantang District
- Hangzhou, Zhejiang 310018
- China
Sciwind Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. IPO | 19-Sep-2025 | Announced | Generating Revenue | |||
| 7. Secondary Transaction - Private | 25-Jul-2023 | Completed | Clinical Trials - General | |||
| 6. Early Stage VC | 01-Mar-2023 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC | 17-Mar-2022 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series C) | 25-Sep-2021 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 14-Oct-2020 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 11-Jan-2019 | $29.5M | $29.5M | Completed | Clinical Trials - General | |
| 1. Early Stage VC | 09-May-2018 | Completed | Clinical Trials - General |
Sciwind Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sciwind Biosciences Patents
Sciwind Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026149479-A1 | Preparation and use of β-klotho/fgfr1-binding protein and conjugate thereof | Pending | 08-Jan-2025 | ||
| WO-2026139062-A1 | Corticotropin releasing factor 2 receptor agonist and use thereof | Pending | 26-Dec-2024 | ||
| WO-2026067799-A1 | Co-agonist of glp-1 receptor and amylin receptor | Pending | 30-Sep-2024 | ||
| AU-2025214331-A1 | Glucagon-like peptide 2 derivative and use thereof | Pending | 31-Jan-2024 | ||
| WO-2025162422-A1 | Glucagon-like peptide 2 derivative and use thereof | Pending | 31-Jan-2024 |
Sciwind Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sciwind Biosciences Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority | ||
| Tencent Investment | Corporate Venture Capital | Minority | ||
| IDG Capital | Venture Capital | Minority | ||
| Loyal Valley Capital | Growth/Expansion | Minority | ||
| Platanus Ventures | Accelerator/Incubator | Minority |
Sciwind Biosciences FAQs
-
When was Sciwind Biosciences founded?
Sciwind Biosciences was founded in 2017.
-
Where is Sciwind Biosciences headquartered?
Sciwind Biosciences is headquartered in Hangzhou, China.
-
What is the size of Sciwind Biosciences?
Sciwind Biosciences has 8 total employees.
-
What industry is Sciwind Biosciences in?
Sciwind Biosciences’s primary industry is Drug Discovery.
-
Is Sciwind Biosciences a private or public company?
Sciwind Biosciences is a Private company.
-
What is Sciwind Biosciences’s current revenue?
The current revenue for Sciwind Biosciences is .
-
How much funding has Sciwind Biosciences raised over time?
Sciwind Biosciences has raised $136M.
-
Who are Sciwind Biosciences’s investors?
LAV (Lilly Asia Fund), Tencent Investment, IDG Capital, Loyal Valley Capital, and Platanus Ventures are 5 of 11 investors who have invested in Sciwind Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
